Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML

Xin Long, PhD, Chris Man, PhD, Padmini Narayanan, PhD, Elizabeth Seashore, MD, Michele Redell, MD PhD

Blood (2019) 134 (Supplement_1): 3731.

https://doi.org/10.1182/blood-2019-129074

Published: 2019

Journal Articles

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Willem K. Smits, Zhongli Chen, MSc, Jules P.P. Meijerink, PhD

Blood (2019) 134 (Supplement_1): 1292.

https://doi.org/10.1182/blood-2019-124721

Published: 2019

Journal Articles

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Lisa Maria Kuhn, Cyrill Schipp, PhD, Daniel Hein, PhD, Bianca Killing, Nan Qin, PhD, Vera H Jepsen, M.Sc., Heinz Ahlert, MSc, BSc, Jasmin Bartl, PhD, Viktoria Marquardt, M.Sc., David Pauck, Kai Völtzke, M.Sc., Jonathan Lim, PhD, Gabriel Leprivier, PhD, Marc Remke, MD, Sanil Bhatia, PhD, Thorsten Rosenbaum, MD, Arndt Borkhardt, MD, Ute Fischer, PhD

Blood (2019) 134 (Supplement_1): 4651.

https://doi.org/10.1182/blood-2019-131406

Published: 2019

Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 406.

https://doi.org/10.1182/blood-2018-99-117577

Published: 2018

Journal Articles

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Jesus Izaguirre-Carbonell, PhD, Christiansen Luke, Robert Burns, PhD, Jesse Schmitz, Chenxuan Li, Rebekah Mokry, Theresa Bluemn, Yongwei Zheng, Demin Wang, PhD, Nan Zhu, PhD

Blood (2018) 132 (Supplement 1): 2599.

https://doi.org/10.1182/blood-2018-99-110463

Published: 2018

Journal Articles

Mice Expressing MYC and Nras Q61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma

Adhithi Rajagopalan, BS, Zhi Wen, PhD, Quinlan Furumo, Erik A. Ranheim, MD PhD, Remington Finn, Evan Flietner, BS, Grant Yun, Yun Zhou, MS, Mei Yu, PhD, Natalie Scott Callander, MD, Marta Chesi, PhD, P. Leif Bergsagel, MD, Robert Burns, PhD, Demin Wang, PhD, Fotios Asimakopoulos, PhDMBBChir,, Jing Zhang, PhD

Blood (2018) 132 (Supplement 1): 1006.

https://doi.org/10.1182/blood-2018-99-116757

Published: 2018

Journal Articles

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Shehroz Aslam, MD, Mustafa Nadeem Malik, MD, Abdul Rafae, MD, Rida Riaz, MBBS, Seren Durer, MD, Ceren Durer, MD, Faisal Mahfooz, MD, Muhammad Jahanzeb Khalil, MD, Jemin Aby Jose, MD, Zunairah Shah, MBBS, Chaudhry Saad Sohail, MD, Maaz Ahmed Yusufi, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5659.

https://doi.org/10.1182/blood-2018-99-115721

Published: 2018

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Sara C. Meyer, MD PhD, Nilabh Ghosh, MSc, Simona Stivala, PhD, Anne Baerenwaldt, PhD, Hui Hao-Shen, Stefan Dirnhofer, MD, Matthias S. Dettmer, MD, Cédric Simillion, PhD, Sophia Chiu, MSc, Matthew Keller, MSc, Maria Kleppe, PhD, Morgane Hilpert, PhD, Andreas S. Buser, MD, Jakob R. Passweg, MDMS, Thomas Radimerski, PhD, Radek C. Skoda, MD, Ross L. Levine, MD

Blood (2017) 130 (Supplement 1): 381.

https://doi.org/10.1182/blood.V130.Suppl_1.381.381

Published: 2017

Journal Articles

Breaking IL7R Signaling-Induced Glucocorticoid Resistance By Small Molecule Inhibitors in T-Cell Acute Lymphoblastic Leukemia

Jordy Van Der Zwet, MD, Jules Meijerink, PhD, Jessica Buijs-Gladdines, Yunlei Li, PhD, Rob Pieters, MD PhD

Blood (2017) 130 (Supplement 1): 2534.

https://doi.org/10.1182/blood.V130.Suppl_1.2534.2534

Published: 2017

Journal Articles

Precision Medicine Assays Detect Novel Targetable FLT3 Fusions Amenable to Therapeutic Intervention in a Patient with Refractory Acute Myeloid Leukemia

Bradley A Patay, MD, Andrew Carson, PhD, Timothy J Martins, PhD, Sylvia Chien, Mary-Elizabeth M. Percival, MD MS, Taylor Sekizaki, Cody Hammer, Pamela S. Becker, MD PhD

Blood (2016) 128 (22): 5170.

https://doi.org/10.1182/blood.V128.22.5170.5170

Published: 2016

Journal Articles

MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy

Anna Polak, MSc, Przemyslaw Kiliszek, MSc, Tomasz Sewastianik, MSc, Maciej Szydlowski, PhD, Ewa Jablonska, PhD, Emilia Bialopiotrowicz, PhD, Patryk Gorniak, PhD, Sergiusz Markowicz, PhD, Eliza Nowak, MSc, Monika A. Grygorowicz, MSc, Dominika Nowis, MDPhD, Jakub Golab, MD PhD, Sebastian Giebel, MD PhD, Ewa Lech-Maranda, MD PhD, Krzysztof Warzocha, MD PhD, Przemyslaw Juszczynski, MD PhD

Blood (2015) 126 (23): 4917.

https://doi.org/10.1182/blood.V126.23.4917.4917

Published: 2015

Journal Articles

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

Natalie Galanina, MD, Sonali M. Smith, MD, Chuanhong Liao, PhD, Adam M. Petrich, MD, Bernadette Libao, Ron Gartenhaus, MD, Jason R Westin, MD, Kenneth S. Cohen, MD, James Knost, MD, Walter Stadler, MD, Austin Doyle, MD, Theodore Karrison, PhD, Leo I. Gordon, MD, Andrew M Evens, DO, MS

Blood (2015) 126 (23): 3990.

https://doi.org/10.1182/blood.V126.23.3990.3990

Published: 2015

Journal Articles

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

Gilles M. Leclerc, PhD, Shuhua Zheng, BS, Guy J. Leclerc, PhD, Joanna DeSalvo, BSc, Ronan T. Swords, MDPhDFRCPI FRCPath, Julio C. Barredo, MD

Blood (2015) 126 (23): 1327.

https://doi.org/10.1182/blood.V126.23.1327.1327

Published: 2015

Journal Articles

MEK Inhibition Is a Promising Therapeutic Strategy for MLL -Rearranged Infant ALL Patients Carrying RAS Mutations

Mark JB Kerstjens, MSc, Emma MC Driessen, MD, Merel Willekes, BSc, Sandra S Mimoso Pinhancos, MSc, Rob Pieters, MD PhD, Ronald Stam, PhD

Blood (2014) 124 (21): 919.

https://doi.org/10.1182/blood.V124.21.919.919

Published: 2014

Journal Articles

The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors

Ravi Dashnamoorthy, PhD, Nassera Abermil, MS, PharmD, Afshin Behesti, PhD, Paige Kozlowski, BS, Frederick Lansigan, MD, William B Kinlaw, MD, Ronald Gartenhaus, MD, Graham Jones, PhD DSc, Lynn Hlatky, PhD, Andrew M. Evens, DO, MSc

Blood (2014) 124 (21): 4490.

https://doi.org/10.1182/blood.V124.21.4490.4490

Published: 2014

Journal Articles

Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens

Atsushi Nonami, MDPhD, Chen Zhao, PhD, Liu Qingsong, PhD, Kristen Cowens, Amanda L. Christie, Yongfei Chen, Martin Sattler, PhD, Kwok-Kin Wang, MDPhD, Nathanael S. Gray, PhD, James D. Griffin, MD, Ellen L. Weisberg, PhD

Blood (2014) 124 (21): 3502.

https://doi.org/10.1182/blood.V124.21.3502.3502

Published: 2014

Journal Articles

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

Julie Irving, Elizabeth Matheson, Lynne Minto, Helen Blair, Marian Case, Christina Halsey, Isabella Swidenbank, Frida Ponthan, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Jana Hof, James Allan, Christine Harrison, Josef Vormoor, Arend von Stackelberg, Cornelia Eckert

Blood (2014) 124 (23): 3420–3430.

https://doi.org/10.1182/blood-2014-04-531871

Published: 2014

Includes: Supplemental data

Journal Articles

RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition

Julie Irving, PhD, Elizabeth C. Matheson, MPhil, Lynne Minto, Helen Blair, PhD, Marian Case, MSc, Christina Halsey, MD, PhD, Isabella Swidenbank, MRes, Frida Ponthan, PhD, Renate Kirschner-Schwabe, PhD, Stefanie Groeneveld-Krentz, MSc, Jana Hof, MSc, James Allan, PhD, Christine J. Harrison, PhD, Josef Vormoor, MD, Arend Stackelberg, MD, Cornelia Eckert, PhD

Blood (2013) 122 (21): 823.

https://doi.org/10.1182/blood.V122.21.823.823

Published: 2013

Journal Articles

Targeting The Interactions Of Fatty Acid Metabolism With PI3K/mTOR and MAPK As a Novel Therapeutic Strategy In Diffuse Large B-Cell Lymphoma (DLBCL)

Ravi Dashnamoorthy, PhD, Frederick Lansigan, MD, Wilson L Davis, III, B.S., William B Kinlaw, III, MD, Ronald Gartenhaus, Andrew M Evens, DO, MSc

Blood (2013) 122 (21): 5133.

https://doi.org/10.1182/blood.V122.21.5133.5133

Published: 2013

NARROW

Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Critical Role of Jumonji Domain of JMJD1C in AML Leukemogenesis

Mice Expressing MYC and Nras Q61R in Germinal Center B Cells Develop Highly Aggressive Multiple Myeloma

Targeting Intracellular Signaling Cascades for Patients with Relapsed, Refractory Multiple Myeloma: A Systematic Review of Clinical Trials

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms

Breaking IL7R Signaling-Induced Glucocorticoid Resistance By Small Molecule Inhibitors in T-Cell Acute Lymphoblastic Leukemia

Precision Medicine Assays Detect Novel Targetable FLT3 Fusions Amenable to Therapeutic Intervention in a Patient with Refractory Acute Myeloid Leukemia

MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy

Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial

The NEDD8 Activating Enzyme Inhibitor Pevonedistat Induces ER Stress/UPR-Mediated Cell Death and Rebalances Homeostasis of Pro- and Anti-Apoptotic Proteins in Favor of Cell Death in Acute Lymphoblastic Leukemia Cells

MEK Inhibition Is a Promising Therapeutic Strategy for MLL -Rearranged Infant ALL Patients Carrying RAS Mutations

The Lipid Addiction of Diffuse Large B-Cell Lymphoma (DLBCL) and Potential Treatment Strategies with Novel Fatty Acid Synthase (FASN) Small Molecule Inhibitors

Identification of Wee1 and IGF-1R As Novel Therapeutic Targets for Mutant RAS-Driven Acute Leukemia By Combinatory Chemical Screens

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

RAS Pathway Mutations Are Highly Prevalent In Relapsed Childhood Acute Lymphoblastic Leukaemia, Are Frequently Relapse-Drivers and Confer Sensitivity To MEK Inhibition

Targeting The Interactions Of Fatty Acid Metabolism With PI3K/mTOR and MAPK As a Novel Therapeutic Strategy In Diffuse Large B-Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only